Alembic Pharmaceuticals moves up as its partner NATCO gets USFDA’s tentative nod for Olaparib Tablets

Alembic Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 533573 | NSE: APLLTD

20 Jul 2026 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 829.25, up by 3.90 points or 0.47% from its previous closing of Rs. 825.35 on the BSE.

The scrip opened at Rs. 834.60 and has touched a high and low of Rs. 837.55 and Rs. 828.80 respectively. So far 1666 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1064.70 on 21-Jul-2025 and a 52 week low of Rs. 635.30 on 23-Mar-2026.

Last one week high and low of the scrip stood at Rs. 855.70 and Rs. 813.65 respectively. The current market cap of the company is Rs. 16413.02 crore.

The promoters holding in the company stood at 69.87%, while Institutions and Non-Institutions held 20.12% and 10.01% respectively.

Alembic Pharmaceuticals’ partner NATCO Pharma (NATCO) has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olaparib Tablets, 100 mg and 150 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lynparza Tablets, 100 mg and 150 mg, of AstraZeneca Pharmaceuticals LP (AstraZeneca) for the indication in the approved labelling. The company will distribute the product in the U.S., and its partner NATCO will manufacture Olaparib Tablets, 100 mg and 150 mg.

The Para IV litigation is on-going. Olaparib Tablets, 100 mg and 150 mg, have an estimated market size of around $1.4 billion in the U.S. for twelve months ending March 2026, according to IQVIA. The company has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA.

Alembic Pharmaceuticals is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.

Alembic Pharma Share Price

836.85 -4.75 (-0.56%)

21-Jul-2026 09:41 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1947.50
Dr. Reddys Labs.	1219.30
Cipla	1434.80
Lupin	2484.60
Zydus Lifesciences	1146.25
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.